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p<0.02), (b) prioritization of utilization of services of various 
health functionaries for treatment of and advice for children’s 
illnesses(r=+0.75, p<0.05), and (c) prioritization of households using 
water from different sources(r=+0.975, p<0.02). The method was also 
found to be more rapid (3.3 times) and less costly (6.3 times) compared 
to the traditional household survey method. (RCHA) for prioritization 
of community health problems in a rural community is validated. The 
information thus obtained can be utilized for purposes of health policy 
and program planning, monitoring and evaluation. This is especially 
relevant for micro planning of cancer screening programs in developing 
countries. Repeated use of questionnaires for monitoring disease con-
trol programs must be carefully considered. Further studies to conﬁrm 
and reconﬁrm the results of this study may be done before wider appli-
cation in tobacco control and cancer control of above methodology 
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Objective: Chemotherapy offers slight but signiﬁcant survival ad-
vantage compared to best supportive care.Best supportive care varies 
according to cultural differences. This study was planned to compare 
chemotherapy with best supportive care, set up in the management of 
inoperable lung cancer patients. 
Methods: Seventy-eight patients were included in the study, out of 
which 38 were in the chemotherapy group (standard chemotherapy) 
and 40 were in the supportive care group. Supportive care included 
psychological support from family, nutritional support, family support, 
palliative radiotherapy, pain relief and other symptomatic relief. They 
were followed up for a period of one year. The main outcome measure 
was survival from the date of diagnosis. 
Results: The median survival of patients in the chemotherapy group 
was signiﬁcantly better than that of patients in the supportive care 
group. In patients are non- small cell lung cancer, median survival was 
27.0 weeks in the chemotherapy group and 10.1 weeks the best sup-
portive care group. In patients with small cell lung cancer, this was 15.6 
weeks and 3.9 weeks respectively. 
The improvement in survival with chemotherapy was consistently 
present in subgroups based on stage and performance status. Although 
patients with better performance status had a higher survival beneﬁt 
with chemotherapy, even patients with poor performance status had 
signiﬁcant improvement in survival with chemotherapy. 
In patients with advanced lung cancer, chemotherapy results in a much 
better survival than best supportive care alone. 
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Background: Anemia is the most frequent hematological complication 
of cancer. Epoetin beta (E), an effective treatment of chemotherapy-
induced anemia in patients (pts) with solid tumors was administred 
three-times weekly. This study was to evaluate efﬁcacy and safety of E 
30 000 IU in pts with LC.
Methods: This study was an open-label, single-arm, multicenter trial 
between December 2003 and August 2005. Eligibility criteria were: 
informed consent, age >=18 yrs, WHO performance status 0/2, malig-
nant non-myeloid malignancies, on-going chemotherapy and anemia: 
hemoglobin (Hb) <12 g/dl. E 30 000 IU QW was administered SC for 
up to 16 weeks. Follow-up visits were scheduled after each chemother-
apy cycle. Primary endpoint was Hb response deﬁned as an Hb increase 
of >=2 g/dl (whatever the baseline Hb level) and/or an achievement of 
Hb level of >=12 g/dl or 13 g/dl with Hb levels <11 g/dl or >11 g/dl at 
baseline respectively). Time to Hb response, transfusion requirement, 
mood and cognitive functions were also assessed. Here, we focus spe-
ciﬁcally on the subgroup of pts with LC
Results: 102 pts with LC were enrolled. Characteristics of the popula-
tion are the following: 63% of pts were male and 28% >= 70 years old, 
69% of pts received 1st line chemotherapy (75% were platinum-based 
regimen). Median Hb level at baseline was 10.4 g/dl [7.9-12.3]. At end-
point, median Hb level increased to 13.2 g/dl [9.3-15.0]. Hb response 
rate (RR) was: 54% (IC95: 44-64%), 56.6% (IC95: 43.3-69.9%) in pts 
treated with platinum based regimen and 61.1% (IC95: 38.6-83.6%) 
in pts treated without platinum. E treatment was well tolerated. No 
difference according to age, number of lines of treatment and type of 
chemotherapy. Thromboembolic events related to treatment occurred in 
2.9% of pts. 
Conclusion: Epoetin beta 30 000 IU once weekly is effective and well 
tolerated in anemic pts with lung cancer treated with platinum based 
chemotherapy. Once weekly treatment offers a convenient therapy 
which will improve patient compliance.
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Background: quality of life is an important outcome in lung patient 
treated by second line of chemotherapy. Alopecia may be an important 
part of this quality of life but in fact very few data’s are available.
Objective: the aim of this study is to assess, in patients treated by 
chemotherapy, the impact of alopecia.
Methods: This prospective, single centre study, use a willingness to 
pay method. Advanced LC patients (50 patients planned) were asked 
ﬁrst to assess the impact of alopecia in second line chemotherapy set-
ting from an analogical visual scale (from 0: no impact to 10 major im-
pact); then they participated, in a face to face interview, at the presenta-
tion of a hypothetical scenario with 2 chemotherapies with the same 
efﬁcacy, the same pattern of administration (every 3 weeks, in day care 
hospital) and the same tolerability except for the risk of alopecia: 5% 
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS836
for the product A and 40% for the product B and were asked for their 
willingness to pay for product A. 
Results: At this time, 31 patients had been enrolled: men: 20 (64,5%), 
age: 64,5 ± 11,7 years, hairless: 4 (13%). In analogical visual scale, 
the impact of alopecia were assessed at 4,7 ± 3,5, median: 5. The mean 
amount patients were willing to pay by 3-week chemotherapy cycle is 
83,3 ± 141,7 euros (median 12,5 euros); 12 (38,7%) of the patients are 
not ready to pay for the product A. 
Discussion and Conclusion: complete results and analysis in rela-
tion with the willingness to pay stratiﬁed by sex, age, employment and 
income will be presented at the meeting. 
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Background: There are few data on the economic consequences of 
targeted cancer therapies. 
Objective: This study examined care consumption and management 
costs among patients who received second- or third-line oral erlotinib 
therapy for non small-cell lung cancer (NSCLC). 
Methods: The study involved two observational cohorts of NSCLC 
second- or third-line treated patients. In the ﬁrst, created in 2005 (be-
fore erlotinib became available), the patients received IV chemotherapy 
alone (IV cohort, 233 patients), while the patients in the second cohort, 
created in 2006, received oral erlotinib (oral cohort, 166 patients). Only 
direct costs were taken into account (drug acquisition and administra-
tion, hospitalization, consultation, costs of managing common toxici-
ties). The analysis adopted the payer’s perspective. 
Results: Treatment lasted a similar length in the IV and oral cohorts 
during second-line treatment (94.5 ± 67.5 and 105 ± 79.4 days, p = 
0.07) but was signiﬁcantly longer in the oral cohort during third-line 
therapy line (76.6 ± 96.5 versus and 114.4 ± 74.5 days, p < 0.008). 
There were more women in the oral cohort (41% versus 26.2%, 
p=0.023) and a higher rate of adenocarcinoma (60.8% versus 47.2%, 
p = 0.0043). There was no difference in smoking status or the disease 
stage at diagnosis. Likewise, the rate of conventional hospitalization 
was not different between the two cohorts. In contrast, during 100 days 
of management, the patients in the oral cohort tended to spend less time 
in hospital during second-line treatment (3 ± 6.6 vs 7.7 ± 18.3 days, p = 
0,057), and the difference was statistically signiﬁcant during third-line 
treatment (4.8 ± 11.7 vs 8.7 ± 14 days, p<0.05). Regardless of the line 
of treatment, the oral cohort made signiﬁcantly fewer stays in daycare 
clinics (p<0.001), and received signiﬁcantly less antiemetic treatment 
(p<0.0001), erythropoietin (p<0.005) and G-CSF (p< 0001). In con-
trast, these patients required more treatment for skin rash (p<0.001). 
Monthly management costs per patient in the IV and oral cohorts were 
respectively 3126 and 2750 euros during second-line treatment and 
3026 and 2823 euros during third-line treatment (no signiﬁcant differ-
ence). A sensitivity analysis showed that the results in the IV cohort 
were dependent on the cost of chemotherapy. 
Discussion: One limit of this study is that transport costs were not 
taken into account. Conclusion: In oral cohort, the cost of Erlotinib 
is compensated by the reduction of daycare hospitalization costs and 
the limited cost of medication to treat adverse events compared to IV 
chemotherapy such as erythropoietin or G-CSF. 
Conclusion: These results must be validated by prospective observa-
tional studies focusing on quality of life and the time spent in hospital. 
This study was supported by Roche Pharma France
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Introduction: A prospective cohort study was undertaken to develop 
risk models for neutropenic complications (NC) consisting of severe or 
febrile neutropenia (FN) among cancer patients receiving chemothera-
py. Models are presented of the risk of such events among lung cancer 
patients initiating a new chemotherapy regimen. 
Methods: Of 907 lung cancer patients, data on 1 or more cycles of che-
motherapy were available on 863 lung cancer patients (665 non small 
cell lung cancer [NSCLC] and 198 small cell lung cancer [SCLC]) 
initiating a new chemotherapy regimen at 115 randomly selected 
U.S. oncology practice sites. Univariate and multivariate proportional 
hazards regression analyses were undertaken to assess the time from 
treatment initiation to the initial NC up to 4 cycles of chemotherapy. In 
the absence of events, patients were censored at the last time seen. 
Results: Of the 863 patients with data on at least 1 cycle of chemo-
therapy, NC (or FN) was experienced over a median of 3 cycles in 15% 
(5%) with NSCLC and over a median of 4 cycles in 40% (18%) with 
SCLC. Four evaluable cycles of treatment were completed in 45% and 
58% of patients with NSCLC and SCLC, respectively. Independent 
clinical risk factors for NC in patients with NSCLC include: leukopenia 
(hazard ratio [HR]=2.1); hyperglycemia (HR=1.8); elevated bilirubin 
(HR=2.6) and alkaline phosphatase (HR=1.7); recent surgery (HR=1.8) 
or chemotherapy (HR=2.9); regimens incoporating cisplatin or carbopl-
atin (HR=4.9), docetaxel (HR=2.2), gemcitabine (HR=2.8), or vinorel-
bine (HR=5.1); planned relative dose intensity >85% (HR=1.8) while 
prophylactic myeloid growth factor was associated with a signiﬁcant 
decrease in risk (HR=0.40). Alternatively, signiﬁcant independent risk 
factors for NC among patients with SCLC include: elevated bilirubin 
(HR=3.9); concurrent immunosuppressives (HR=2.0); regimen based 
on topoisomerase inhibitors (HR=5.1) and age >65 years (HR=1.9) 
and thrombocytopenia (HR=3.4) while reduced risk was observed with 
growth factor prophylaxis (HR=0.41). Model ﬁt for both models was 
excellent by a likelihood ratio test (P<.0001). 
Conclusions: Multivariate analysis for NC identiﬁes overlapping as 
well as distinct risk factors for patients with NSCLC and SCLC receiv-
